CAPR Stock Overview
A clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Capricor Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.92 |
| 52 Week High | US$23.40 |
| 52 Week Low | US$2.90 |
| Beta | 4.02 |
| 11 Month Change | -8.02% |
| 3 Month Change | 313.10% |
| 1 Year Change | 534.90% |
| 33 Year Change | 459.76% |
| 5 Year Change | 981.14% |
| Change since IPO | -54.95% |
Recent News & Updates
Recent updates
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Sep 18
Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel
Jul 30Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up
May 08Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet
Apr 19We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Apr 16Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 03Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
Dec 13Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Aug 13A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Nov 03Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03
Aug 10Shareholder Returns
| CAPR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.9% | -6.5% | -1.0% |
| 1Y | 534.9% | 14.6% | 30.3% |
Return vs Industry: CAPR exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: CAPR exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| CAPR volatility | |
|---|---|
| CAPR Average Weekly Movement | 25.3% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CAPR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CAPR's weekly volatility has increased from 15% to 25% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 102 | Linda Marbán | www.capricor.com |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
Capricor Therapeutics, Inc. Fundamentals Summary
| CAPR fundamental statistics | |
|---|---|
| Market cap | US$839.37m |
| Earnings (TTM) | -US$34.11m |
| Revenue (TTM) | US$23.23m |
37.0x
P/S Ratio-25.2x
P/E RatioIs CAPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAPR income statement (TTM) | |
|---|---|
| Revenue | US$23.23m |
| Cost of Revenue | US$45.35m |
| Gross Profit | -US$22.13m |
| Other Expenses | US$11.99m |
| Earnings | -US$34.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | -95.25% |
| Net Profit Margin | -146.86% |
| Debt/Equity Ratio | 0% |
How did CAPR perform over the long term?
See historical performance and comparison